Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors.

Indeed, while the precocious reduction of neutrophil counts during CDK4/6i therapy showed a trend toward an association with better patient PFS, CDK4/6i-induced reduction of monocyte and platelet counts was even associated with a trend toward worse PFS ( Supplemental Figure 5–7 ).

also in 53,322 other papers